Publication number: 20230255975
Abstract: Provided herein are methods of using a compound provided herein (e.g., Compound 1, Compound 2, Compound 3, Compound 4, Compound 5, Compound 6, or Compound 7, or a stereoisomer or mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof), in combination with a second) active agent for treating cancer. The second active agent is one or more of a PLK1 inhibitor, a BRD4 inhibitor, a BET inhibitor, an NEK2 inhibitor, an AURKB inhibitor, an MEK inhibitor, a PHF19 inhibitor, a BTK inhibitor, an mTOR inhibitor, a PIM inhibitor, an IGF-1R inhibitor, an XPO1 inhibitor, a DOT1L inhibitor, an EZH2 inhibitor, a JAK2 inhibitor, a BIRCS inhibitor, or a DNA methyltransferase inhibitor.
Type:
Application
Filed:
June 24, 2021
Publication date:
August 17, 2023
Inventors:
Aarif AHSAN, Kamlesh BISHT, Chad BJORKLUND, Jennifer Erin FLYNT, Chih-Chao HSU, Danny Vijey JEYARAJU, Maria ORTIZ-ESTEVEZ, William Edward PIERCEALL, Anjan THAKURTA, Fadi George TOWFIC
